1053549-93-1

Basic information

• Product Name: Acetic acid (R)-1-[(1S,2R)-2-hydroxy-1-((2S,3R,4S,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecylcarbamoyl]-tricosyl ester
• Synonyms: Acetic acid (R)-1-[(1S,2R)-2-hydroxy-1-((2S,3R,4S,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecylcarbamoyl]-tricosyl ester
• CAS NO: 1053549-93-1
• Molecular Weight: 1232.82
• Mol File: 1053549-93-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Acetic acid (R)-1-[(1S,2R)-2-hydroxy-1-((2S,3R,4S,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecylcarbamoyl]-tricosyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid (R)-1-[(1S,2R)-2-hydroxy-1-((2S,3R,4S,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecylcarbamoyl]-tricosyl ester(1053549-93-1)
• EPA Substance Registry System: Acetic acid (R)-1-[(1S,2R)-2-hydroxy-1-((2S,3R,4S,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadecylcarbamoyl]-tricosyl ester(1053549-93-1)

Safety Data

• Hazardous Substances Data: 1053549-93-1(Hazardous Substances Data)

Upstream product

• 148289-50-3 (2R,3R)-1,3-Di-O-benzyl-2-O-(methylsulfonyl)-4-octadecene-1,2,3-triol 
• 148289-52-5 (2S,3R)-2-amino-1,3-(dibenzyloxy)-octadeca-4-ene 
• 148289-49-0 (2R,3R)-1,3-Di-O-benzyl-4-octadecene-1,2,3-triol 
• 25791-20-2 (n-tetradecyl)triphenylphosphonium bromide 
• 112-71-0 1-Bromotetradecane 
• 143615-35-4 2,3,4,6-tetra-O-benzyl-D-galactopyranosyl fluoride 

Relevant articles and documents

Structure-activity relationship of α-galactosylceramides against b16- bearing mice

Agelasphin-9b, (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-16-methyl-2-[N- ((R)-2-hydroxytetracosanoyl)-amino]-1,3,4-heptadecanetriol, is a potent antitumor agent isolated from the marine sponge Agelas mauritianus. Various analogues of agelasphin-9b (a lead compound) were synthesized, and the relationship between their structures and biological activities was examined using several assay systems. From the results, KRN7000, (2S,3S,4R)-1-O-(α- D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol, was selected as a candidate for clinical application.